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Antibiotic treatment has emerged as a promising strategy to sterilize and kill filarial nematodes due to their dependence on their endosymbiotic bacteria, Wolbachia. Several studies
have shown that novel and FDA-approved antibiotics are efficacious at depleting the filarial
nematodes of their endosymbiont, thus reducing female fecundity. However, it remains
unclear if antibiotics can permanently deplete Wolbachia and cause sterility for the lifespan
of the adult worms. Concerns about resistance arising from mass drug administration
necessitate a careful exploration of potential Wolbachia recrudescence. In the present
study, we investigated the long-term effects of the FDA-approved antibiotic, rifampicin, in
the Brugia pahangi jird model of infection. Initially, rifampicin treatment depleted Wolbachia
in adult worms and simultaneously impaired female worm fecundity. However, during an 8month washout period, Wolbachia titers rebounded and embryogenesis returned to normal.
Genome sequence analyses of Wolbachia revealed that despite the population bottleneck
and recovery, no genetic changes occurred that could account for the rebound. Clusters of
densely packed Wolbachia within the worm’s ovarian tissues were observed by confocal
microscopy and remained in worms treated with rifampicin, suggesting that they may serve
as privileged sites that allow Wolbachia to persist in worms while treated with antibiotic. To
our knowledge, these clusters have not been previously described and may be the source of
the Wolbachia rebound.

Author summary
Onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) are two neglected
tropical diseases caused by filarial nematodes, which harbor the endosymbiotic bacteria,
Wolbachia. Major efforts to discover new drugs to treat these diseases have led to the

PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008623 July 8, 2020

1 / 17

PLOS PATHOGENS

Competing interests: Emilie Lefoulon, Travis Clark
and Barton Slatko are employed by New England
Biolabs. This does not alter our adherence to all
PLOS Pathogens policies on sharing data and
materials.

The endosymbiont Wolbachia rebounds following antibiotic treatment

discovery of novel compounds including those that target Wolbachia. We investigated the
long-term effects of rifampicin on the filarial nematode, Brugia pahangi, and its endosymbiont, Wolbachia, in an in vivo rodent model of infection. Initially, Wolbachia titers were
significantly reduced by 95% and female fecundity was impaired shortly after treatment. 8
months later however, Wolbachia rebounded and embryogenesis returned to normal.
Sequence analysis of the Wolbachia genome revealed that despite the population bottleneck and recovery, no genetic changes occurred that could account for the rebound. Clusters of Wolbachia were observed within the ovaries of female worms throughout the
entire 8-month study. These clusters may sequester Wolbachia and allow the bacteria to
persist during antibiotic treatment, thereby enabling them to repopulate ovarian tissues
and ensuring their vertical transmission to future generations of microfilariae.

Introduction
Onchocerciasis, commonly known as river blindness, and lymphatic filariasis (LF), commonly
known as elephantiasis, are neglected tropical diseases caused by filarial worms that together
affect an estimated 86 million people worldwide [1]. Approximately 1.2 million people are
visually impaired due to river blindness, while 12 million people with LF have complications
due to elephantiasis [1]. River blindness is caused by the release of thousands of microfilariae
(mf) from adult Onchocerca volvulus females residing in subcutaneous tissues. Mf migrate
through the skin causing severe itching and skin depigmentation and also migrate to the ocular region where they induce an inflammatory response that can lead to blindness [2]. LF is
caused by Wuchereria bancrofti, Brugia malayi and B. timori worms that reside in the lymphatic tissues where they cause tissue damage. While many infections are asymptomatic, individuals that develop the disfiguring disease often experience pain and severe lymphedema
typically in the arms, legs, breasts and genitalia [2]. This can result in stigma associated with
elephantiasis and extreme economic loss for individuals suffering from this disease [3]. The
years lived with disability (YLDs) for LF and onchocerciasis are estimated to be 1.4 million
and 1.3 million, respectively [1].
Current treatments primarily target the mf and not the adult worms, which are capable of
surviving in their human host for 10–14 years for O. volvulus and 6–8 years for Brugia spp.
[2,4–9]. For this reason, international control programs require annual or biannual mass drug
administration of drugs in order to reduce transmission rates. However, given the longevity
and high fecundity of these worms and the current lack of drugs that kill the adult worms, it is
unlikely that the WHO goal of eliminating LF and onchocerciasis by 2030 will be met when
microfilaricidal drugs are used alone [10–15]. The inability to reduce transmission rates with
microfilaricides is compounded by the fact that ivermectin (IVM) cannot be distributed in
areas co-endemic for another filarial nematode, Loa loa, due to the risk of severe adverse
events, especially toxic encephalopathy when individuals are co-infected with high loads of L.
loa mf [16,17].
Onchocerca, Wuchereria and Brugia spp., like many other species of filarial nematodes, harbor an intracellular endosymbiont, Wolbachia, which is important for female worm fecundity
and survival [18–22]. Loa loa, however, lacks this bacterium, and efforts are underway to
develop anti-Wolbachia drugs to eliminate this bacterium, thereby resulting in death of adult
worms. In clinical trials conducted on patients with onchocerciasis and lymphatic filariasis,
doxycycline was shown to deplete Wolbachia and eventually eliminate the adult worms after
about 1–2 years [23,24]. Doxycycline however requires lengthy dosing regimens (100–200 mg
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daily for 4–6 weeks) and is therefore not practical for mass drug distribution. In addition,
doxycycline is contraindicated in children 8 years and younger and because it is in pregnancy
category D, should not be given to pregnant women [2].
Several studies have recently shown that short courses of 7- and 14-days of anti-Wolbachia
compounds hold promise as excellent drugs to treat onchocerciasis and LF [25–29]. Studies by
Hübner et al. however, showed that suboptimal treatment regimens of doxycycline in the Litomosoides sigmodontis infection model did not lead to a sustained reduction in Wolbachia loads
in worms 14–18 weeks post-treatment and that longer term studies were needed to assess permanent sterilization of female adult worms [27,29]. Although West African cattle infected
with Onchocerca ochengi are excellent hosts for long-term studies to evaluate the efficacy of
antibiotics for the treatment of human onchocerciasis [30–36], the purpose of our study was to
investigate the long-term effects of rifampicin in a rodent model of infection. In the present
study, we investigated the use of jirds infected with Brugia pahangi to assess the effects of
rifampicin on Wolbachia and worm survival in an 8-month time course study in which Wolbachia titers were determined using adult worms recovered from animals treated with a oneweek dosing regimen of rifampicin.

Results
The endosymbiont Wolbachia rebound after 8 months following
rifampicin treatment without genetic change
The research objective was to determine the long-term effects of antibiotic treatment on filarial
worms and their endosymbiont, Wolbachia. We hypothesized that rifampicin would deplete
worms of Wolbachia which would eventually lead to adult worm death in jirds infected with
Brugia pahangi. Wolbachia titers in adult male and female worms were determined by qPCR
at 1 week, 6 weeks, 17 weeks and 8 months post-first dose following the protocol by McGarry
et al [37]. The relative abundance of single copy genes encoding the Wolbachia surface protein
(wsp) were normalized to that of Brugia glutathione-S-transferase gene (gst) [28,29,38–40]. At
the 1-week timepoint, Wolbachia titers were significantly reduced by 95.2% in female worms
(Fig 1A). By 6 weeks however, the reduction in Wolbachia titers was reduced by 81.3% compared to those of control worms and by 17 weeks, titers were reduced by 77%. At 8 months,
Wolbachia titers returned to levels similar to those of control worms, i.e. there was a 0% reduction in Wolbachia titers (Fig 1A). Wolbachia titers from male worms followed a similar trend
of rebound (Fig 1B).
Although there was a significant effect of rifampicin on Wolbachia titers at early timepoints
(S1 Table), rifampicin did not reduce the number of adult worms recovered at the time of necropsy at any of the timepoints, i.e. no macrofilaricidal effects were observed (S1 Fig).
To determine if the rebound in Wolbachia occurred as a result of genome changes (e.g.
antibiotic resistance/tolerance), we sequenced Wolbachia genomes using hybridization probecapture method from the treatment and vehicle groups at the 1-week and 8-month timepoints
[41]. On average ~90,000 PacBio CCS reads were generated per sample, which amounts to
~150× coverage of the genome (S2 Table). A complete circularized reference genome
(1,072,983 bp) was assembled using the 1-week vehicle group and sequence variants were identified in each group with respect to the reference. Variants occurring within the genomic
regions likely representing nuclear Wolbachia transfers (nuwts [42]) were excluded from the
analysis.
One single nucleotide variant (SNV) and five insertion/deletion variants (INDEL) were
identified and their allele frequencies were estimated based on the number of reads that support each allele in each sample (S3 Table). The SNV (C-to-T substitution) occurred within the
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Fig 1. Wolbachia titers return to control levels 8 months after rifampicin treatment. Female and male Brugia pahangi from jirds treated with rifampicin
were analyzed by qPCR to determine Wolbachia titers at each timepoint. Mean percent reductions of Wolbachia wsp/gst ratios from female (A) and male (B)
adult worms are shown at 1-week, 6-weeks, 17-weeks and 8-months post-first dose. Data shown are medians and the boxes are the 25th and 75th percentiles
with ��� P<0.001 and � P<0.05. n = 2–9 jirds per treatment group per timepoint. Additional information is shown in S1 Table.
https://doi.org/10.1371/journal.ppat.1008623.g001

ORF of a short-chain dehydrogenase/reductase family (SDR) oxidoreductase and was predicted to be a synonymous variant and therefore a silent mutation. The allele frequency of this
variant increased from 5.1% in the 1-week vehicle group to 35.5% in the 8-month rifampicin
group (Fisher’s exact test P-value: 3.2×10−5), which was the only variant whose allele frequency
displayed a statistically significant change. The INDEL variants invariably occurred within
homopolymer regions (9–13 consecutive bases of A or T). Homopolymeric tracts are mutational hotspots because they are vulnerable to slippage errors during replication and transcription [43]. However, INDEL calling is error-prone around homopolymer runs (due to
sequencing and PCR errors), and we cannot exclude the possibility that these INDELs are
false-positive variants [44]. These data suggest that, despite the population bottleneck and
recovery, the genetic change in Wolbachia after rifampicin treatment likely did not occur.

Female worm fecundity is significantly reduced shortly after treatment but
returns to control levels by 17 weeks
Commensurate with the depletion of Wolbachia 1 week after the first dose of rifampicin, we
observed a significant impact on embryogenesis 6 weeks post-antibiotic treatment. This was followed by a gradual rebound in Wolbachia and return to normal embryogenesis by 17 weeks.
The fecundity of female B. pahangi at each timepoint was assessed by counting the number
of mf released after worms were removed from the animals and incubated in vitro for 18
hours. Worms from rifampicin treated jirds at the 1- and 6-week timepoint showed a significant reduction in the number of mf that were shed compared to worms from the vehicle group
(43.4% reduction, P<0.05 and 86.3% reduction, P<0.0001, respectively) (Fig 2). Female fecundity returned to control levels after 17 weeks and remained at control levels for up to 8
months.
Embryograms of female worms were also analyzed to determine the effects of rifampicin on
the developing stages of mf within the reproductive tract of female worms. Results showed that
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Fig 2. Rifampicin decreases mf shedding from female worms up to 6 weeks, followed by a return to normal by 17 weeks. The number of mf shed
overnight by adult female worms that were recovered 1 week, 6 weeks, 17 weeks and 8-months post-first dose is shown for each timepoint. Mf shed
overnight at the 1- and 6-week timepoint were significantly reduced (� P<0.05 and ���� P<0.0001, respectively). Data are shown as median ± 95% CI.
n = 10–26 female worms from n = 2–9 jirds per treatment group per timepoint.
https://doi.org/10.1371/journal.ppat.1008623.g002

developmental stages from female worms recovered from rifampicin treated jirds at the
6-week timepoint exhibited a significant decrease in healthy embryos and an increase in
degenerated embryos compared to those from both the control group at the 6-week timepoint,
and the rifampicin group at the 1-week timepoint, where little disruption was observed (Fig 3
and S4 Table). The decrease in fecundity and disruption of embryogenesis however were not
observed at later timepoints suggesting that embryonic development of mf returned to control
levels following the rebound of Wolbachia.

Cellular analysis reveals the rebound is derived from clusters of Wolbachia
As an independent method of analyzing Wolbachia titer, we performed fluorescence confocal
analysis to image Wolbachia and host cell nuclei as previously described by Landmann et al.,
Serbus et al. and Foray et al. [45–49].
Fluorescence imaging of the distal tip region of the ovaries revealed that Wolbachia were
nearly depleted from germline tissues at the 1-week timepoint, but they began to increase in
number at later timepoints (Fig 4A). Interestingly, large densely packed “clusters” of

Fig 3. Rifampicin treatment leads to impaired embryogenesis by the 6-week timepoint but normal developmental stages return by 17 weeks. Embryonic stages
found within the ovaries and uteri from female worms from the vehicle and treated groups were counted 1 week, 6 weeks, 17 weeks and 8 months post-first dose. There
was a significant decrease in the frequency of healthy embryos across all developmental stages of embryogenesis at the 6-week timepoint (���� P<0.0001). Percentages of
degenerated embryos (gray) were also determined for each timepoint. Data are presented as mean ± SEM. n = 6–9 female worms from n = 2–9 jirds per treatment group
per timepoint.
https://doi.org/10.1371/journal.ppat.1008623.g003
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Fig 4. Rebound of Wolbachia at later timepoints may be driven by clusters. Ovaries were removed from individual female worms, fixed and stained for host
nuclei (magenta) and Wolbachia (red). (A) Wolbachia are depleted at 1- and 6-weeks post-treatment but begin to rebound by 17 weeks. (B) Clusters of Wolbachia
are seen in ovaries from vehicle and rifampicin worms; actin (green) stained with phalloidin; Wolbachia (red) stained with propidium iodide and host nuclei
(magenta) stained with DAPI. (C) Wolbachia were quantified by counting number of puncta within the clusters (left) and in the periphery of the clusters (right). (D)
Clusters were analyzed from worms collected at 6 weeks (n = 36–46), 17 weeks (n = 6–8) and 8 months (n = 34–52). Vehicle control worms in yellow and worms
from rifampicin treated groups in red. Peripheral Wolbachia were reduced in females recovered from rifampicin treated jirds at the 6-week timepoint only
(P = 0.05). Data are presented as median ± 95% CI.
https://doi.org/10.1371/journal.ppat.1008623.g004

Wolbachia (Fig 4B) were observed in worms recovered from both the vehicle and treated
groups at each timepoint. When Wolbachia were quantified in each of the clusters from ovaries (Fig 4C), results showed there were no significant differences between the treated and control groups with respect to the Wolbachia density (puncta per area of cluster, Fig 4D).
However, Wolbachia in the peripheral areas around the clusters were significantly reduced
(P = 0.05) in the worms from the rifampicin group at 6-weeks but not at the later timepoints
(Fig 4D).
The presence of clusters with densely packed Wolbachia in ovaries from both rifampicin
treated and control worms suggests that despite clearance of bacteria from the areas outside
the clusters, the Wolbachia nevertheless persisted within the clusters and may be the source of
the rebound. Analyses were not conducted on male worms as the focus of the work was on
female fecundity and embryogenesis. We postulate that similar clusters will be associated with
male worms, possibly in the hypodermal areas and, as with females, are likely responsible for
the rebound.

Discussion
Major efforts to identify new drugs to treat the adult stage (macrofilariae) of Onchocerca volvulus have led to the discovery of novel anti-Wolbachia compounds. These studies demonstrated
that their respective anti-Wolbachia compounds significantly reduced Wolbachia titers in
worms from animals treated with short courses of quinazolines and Tylosin analogs after 16–
18 weeks post-first dose [26,27,29,40,50]. In addition, a one-week combination treatment of
rifampicin and albendazole resulted in a greater than 99% reduction in Wolbachia levels in B.
malayi infected SCID mice [28]. Clinical trials further revealed that albendazole either alone or
in combination with antibiotics dramatically reduced Wolbachia levels [51,52]. With the
recent discoveries of new anti-wolbachial drugs, we explored the Wolbachia/worm relationship in vivo to better understand the outcomes of antibiotic exposure. The aim of this study
was to determine the longer-term effects of rifampicin on female worm survival and fecundity
and Wolbachia titers using the Brugia pahangi infected jird model.
Although macrofilaricidal effects were not observed following treatment with rifampicin,
Wolbachia titers and female fecundity were significantly affected 1 week post-first dose. Wolbachia titers were reduced by >95% in female worms from rifampicin treated animals at the
1-week timepoint compared to those of worms from vehicle animals. The extensive reduction
of Wolbachia titers in adult worms has been previously described in other rodent studies with
filarial worms, but the studies were terminated 16–18 weeks post-treatment [26,27,29,40,50],
and the long-term effects of antibiotic treatment on filarial worms and their Wolbachia were
not evaluated in these models.
Our present long-term study showed that even though Wolbachia were almost completely
eliminated at early timepoints, Wolbachia rebounded to levels similar to those of control
worms 8 months after rifampicin dosing. Female worms recovered from this timepoint were
also fully reproductive, similar to female worms from the control group. Thus, despite qPCR
data that showed a >95% reduction in Wolbachia titers, Wolbachia rebounded and returned

PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008623 July 8, 2020

7 / 17

PLOS PATHOGENS

The endosymbiont Wolbachia rebounds following antibiotic treatment

to levels comparable to those of control worms, suggesting that this level of elimination is not
sufficient to ensure permanent elimination and permanent female sterility. This finding parallels the rebound of Wolbachia titers in O. ochengi from cattle treated with a short, intensive
regimen of oxytetracycline (10 mg/kg QD for 14 days) reported by Gilbert et al. [32], and suggests that this jird model is a suitable alternative for long-term studies (up to 8 months) in situations where cattle models cannot be conducted.
The dosage of rifampicin used in the present study was not likely suboptimal since previous
studies with B. malayi infected SCID mice showed that 25 mg/kg rifampicin twice a day for 7
days resulted in reductions in Wolbachia comparable to the clinical dosage of doxycycline that
caused >90% Wolbachia depletion [25]. While we saw the expected reduction in Wolbachia at
early timepoints, the reduction was not sustained, and Wolbachia rebounded. Comparison of
the genetic profiles of Wolbachia genomes from the early and late timepoints revealed that
despite the population bottleneck and recovery, no genetic changes occurred in Wolbachia
that could account for the rebound.
The significance of the rebound in this bacteria/worm symbiosis was evident when low
titers of Wolbachia, which initially led to the reduction of late-stage embryos and microfilariae
at 1- and 6- weeks, was later followed by the return of developing embryos and microfilariae
released by female worms. This recovery back to control levels was commensurate with Wolbachia rebound, in line with evidence showing the dependence of female worms on Wolbachia
to maintain their reproductive output [21,32,49,53–55].
Direct visualization of worm ovaries using fluorescence confocal microscopy revealed two
distinct populations of Wolbachia: “clusters” of Wolbachia that were found within the female
ovaries and “peripheral” Wolbachia that were found surrounding the clusters. For the Wolbachia within clusters, we found no significant differences in bacterial cluster amount, size, or
density between rifampicin and control treatments, suggesting that these clusters do not
respond to antibiotics, at least at the dosages used in this study. In contrast, we found that
rifampicin significantly reduced the peripheral Wolbachia surrounding the clusters at 6 weeks.
To our knowledge, these clusters have never before been identified in any Wolbachia-nematode system, and we believe that the clusters could serve as a reservoir of bacteria that can
repopulate the germline tissue after antibiotic treatment.
Since genome sequencing of the rebounded Wolbachia showed there were no gene changes
that could account for the persistence, we postulate that the clusters are privileged sites in
which Wolbachia persist in a low or inactive metabolic state, similar to what occurs with intracellular Toxoplasma gondii bradyzoites [56,57] and pathogenic intracellular bacteria including
Mycobacterium tuberculosis, Treponema pallidum, Chlamydia spp. and Salmonella enterica
which can cause persistent and latent infections [58–66]. Interestingly, bacterial toxin-antitoxin (TA) genes of the RelEB family thought to cause persister cell formation in insect-associated Wolbachia, were absent in Wolbachia from filarial nematodes, suggesting that TAs may
not be involved in persister formation of Wolbachia within the clusters and that other mechanisms are likely at play [67–70].
Although the molecular mechanisms of persister formation is not known in the Wolbachiaworm relationship, Wolbachia may respond in some manner to their low numbers and repopulate the ovarian tissues by moving from the clusters to the peripheral areas within the ovaries
or by migrating into the worm’s pseudocoelom [46,71] and back into the ovaries, thereby
ensuring their vertical transmission for future generations of microfilariae.
Further studies to define the nature of these clusters and wolbachial persistence will yield
new information on the cell biology of this bacteria-worm symbiosis and may reveal similar
strategies used by various pathogens that allow them to persist and remain latent within their
hosts.

PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008623 July 8, 2020

8 / 17

PLOS PATHOGENS

The endosymbiont Wolbachia rebounds following antibiotic treatment

Conclusion
We describe the effects of rifampicin treatment on the Wolbachia-Brugia pahangi relationship
over an 8-month period in a rodent model. Wolbachia numbers were significantly reduced
after initial treatment but subsequently rebounded along with a corresponding return of
embryogenesis and fecundity in female worms. This in vivo B. pahangi/jird model serves as a
useful tool to evaluate the long-term effects of antibiotics on Wolbachia depletion and female
worm fecundity and provides information that may impact the clinical use of antibiotics to
treat filarial diseases.
This study also provides insight into the Wolbachia-worm relationship with the discovery
of two different populations of Wolbachia within the ovaries of these filarial worms: clusters of
Wolbachia and peripheral Wolbachia, the former of which may account for the rebound of
Wolbachia following antibiotic treatment. To our knowledge, clusters of Wolbachia have
never before been identified in any Wolbachia-nematode system and may represent sequestered populations of this endosymbiont within Brugia pahangi ovaries.

Methods
Ethics statement
All animal studies were performed under the University of California, San Francisco Institutional Animal Care and Use Committee (IACUC) approvals AN109629-03 and AN173847-02
and adhered to the guidelines set forth in the NIH Guide for the Care and Use of Laboratory
Animals and the USDA Animal Care Policies.

Animal infections
For dosing studies on adult worms, male Mongolian jirds 50–60 grams, 5–7 weeks in age (Meriones unguiculatus, Charles River Laboratories International, Inc., Wilmington, MA) were
injected intraperitoneally (IP) with third-larval stage Brugia pahangi (University of MissouriColumbia) and treated 3 months later when larvae developed into adult worms.

Drug dosages
Rifampicin (Research Products International Corp., Prospect, IL) was dissolved in 55% polyethylene glycol 400 (Sigma), 25% propylene glycol (Sigma), 20% water at a concentration of 5 mg/mL,
and animals were given oral doses of 25 mg/kg twice a day for 7 days. We selected the dosage 25
mg/kg BID for 7 days based on findings from Aljayyoussi et al, 2017 which reported rifampicin
dosages of 15 mg/kg QD for 7 days, 35 mg/kg QD for 7 days, or 25 mg/kg BID for 7 days resulted
in reductions in Wolbachia of 97.7%, 98.2% and 99.5%, respectively [25]. They found 25 mg/kg
BID x 7 days to be superior to doxycycline 25 mg/kg BID treatment for four weeks (P>0.0001)
and not significantly inferior from doxycycline 25 mg/kg BID treatment for six weeks [25].

PK analyses
To determine the level of exposure of rifampicin in treated animals, blood was collected from
the saphenous vein in Am-heparinized tubes and centrifuged at 2,000 x g for 15 min at 4˚C.
Blood was collected 0.5 hour, 1 hour, 3 hours and 6 hours post-first dose. The second dose was
given 8 hours post-first dose and blood was collected 24 hours post-first dose. Plasma was collected and stored at -80˚C prior to shipment to Integrated Analytical Solutions (Berkeley, CA)
for plasma analysis (S2 Fig). Calibration standards, QC samples and study samples were processed for LC/MS/MS analysis by precipitating 10 μL of each sample with 3 volumes of ice cold
Internal Standard Solution (acetonitrile containing 50 ng/mL dextromethorphan). The
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precipitated samples were centrifuged at 6100g for 30 min and an aliquot of each supernatant
was transferred to an auto sampler plate and diluted in water with 2 volumes of 0.2% formic
acid.

Necropsies
Vehicle and rifampicin treated jirds were necropsied 1 week, 6 weeks, 17 weeks and 8 months
post-first dose. Animals were dissected and peritoneal cavities were washed with 100 mL of
PBS to collect adult worms and mf that had been released from female worms. Adult worms
were separated by sex, counted and processed for subsequent analyses. Mf from the peritoneal
cavity were quantified by mixing peritoneal wash 9:1 (v/v) with 0.04% methylene blue:water
and counted using an inverted microscope. Data from each timepoint are from three replicate
studies, except for the 17-week timepoint, in which the data are from one set. All animals were
euthanized at their intended timepoints and no adverse events were observed. However, one
animal had ascites, but was otherwise healthy at the 8-month timepoint.

qPCR analysis of Wolbachia in adult Brugia pahangi
Adult worms collected during necropsies were snap-frozen in a dry-ice and ethanol bath prior
to storage at -80˚ C. gDNA was extracted from individual female worms or from 4–25 male
worms using a DNEasy Blood & Tissue Kit (QIAGEN) according to the manufacturer’s
instructions. Genomic DNA was quantified using a NanoDrop Onec (Thermo Fisher Scientific) and qPCR was performed using a Geneoecopia 2x All-in-One Master Mix (Cat #QP00101) in a Bio-Rad CFX Connect RT-PCR thermocycler. The single copy gene, Wolbachia surface protein (wsp), was used to quantify Wolbachia titers and the single copy gene, glutathione-S-transferase (gst), was used to quantify Brugia titers following the protocol of McGarry
et al. [37]. Primers used for qPCR were based on wsp forward: 5’-CCCTGCAAAGGCACAA
GTTATTG-3’; wsp reverse: 5’-CGAGCTCCAGCAAAGAGTTTAATTT-3’; gst foward: 5’-GA
GACACCTTGCTCGCAAAC-3’; gst reverse: 5’-ATCACGGACGCCTTCACAG-3’. For gst
amplification the following cycles were used: 95˚C for 15 minutes, followed by 36 cycles of
denaturation at 94˚C for 15 seconds, annealing at 55˚ C for 30 seconds and elongation at 72˚ C
for 30 seconds. Melting curve analysis was conducted by heating to 95˚C for 1 minute, annealing at 55˚C for 30 seconds and heating to 97˚C. For wsp amplification: samples were heated at
95˚ C for 15 minutes, followed by 40 cycles of denaturation at 94˚C for 10 seconds, annealing
at 55˚C for 20 seconds and elongation at 72˚C for 15 seconds. Melting curve analysis was conducted by heating to 95˚C for 1 minute, annealing at 55˚C for 30 seconds and heating to 97˚C.

Wolbachia genome sequencing
Total genomic DNA was extracted from Brugia pahangi worms recovered from 1-week and
8-month timepoints using DNeasy Blood & Tissue Kit (QIAGEN) following the manufacturer’s protocol and quantified using Qubit (Invitrogen). Genomic DNA was subjected to hybridization probe-capture (adaptation of the protocol of Geniez et al. and protocol of Lefoulon
et al.) to enrich for Wolbachia DNA using biotinylated probe-baits and magnetic streptavidin
beads [41,72]. Prior to capture, genomic DNA was sheared using NEBNext FSII for 30 min at
37˚ and ligated to NimbleGen SeqCap adapters (NEBNext Ultra II kit), followed by AMPure
bead purification (0.9X), PCR amplification and purification through AMPure beads (0.9X).
The barcoded samples were then pooled (~400 ng per sample) and hybridization of DNA with
Wolbachia specific EZ library probes was performed according to SeqCap EZ HyperCap protocol v1.0 (NimbleGen). The captured DNA library was amplified by PCR, purified using
AMPure bead (0.9X), and subjected to PacBio circular consensus sequencing (CCS). A
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reference wBp genome was assembled with Canu v1.9 [73] from the control sample (1-week
vehicle group) after the CCS reads were trimmed to remove residual adapter sequences using
seqtk. To minimize assembly errors due to the presence of B. pahangi sequences derived from
nuclear Wolbachia transfers (nuwts), a draft assembly was first generated using all available
reads, and then reads (longer than 3 kb) that mapped to the assembly without clipping were
collected using minimap v2.17 [74] and assembled to produce a second draft assembly, which
was then circularized using Circlator [75]. Assembly errors were further corrected through
manual curation and Pilon v1.23 [76]. Genome annotation was performed using PGAP [77]
and DFAST v1.2.4 [78]. Genetic variants (SNPs and indels) were called across samples by
DeepVariant [79] after non-clipped CCS reads were aligned to the wBp reference genome
using minimap2. The depth-of-coverage patterns of clipped reads (that span the junctions
between nuwts and B. pahangi DNA) along the Wolbachia genome were exploited to infer the
location of regions that show sequence similarity to nuwts using samtools [80] and sequana_coverage v0.7.1 [81]. Using VCFtools v0.1.17 [82], false-positive variants occurring within
these putative nuwts regions were filtered and excluded from further analyses. Finally, SnpEff
v4.3 [83] was used to annotate and predict the effects of the remaining variants. The statistical
significance of allele frequency differences was determined with Fisher’s exact test.

Embryograms and microfilariae overnight shed
Individual adult female worms (n = 12–24 females per treatment group) from vehicle and rifampicin treated jirds were maintained overnight in 24-well plates with 500 μL of RPMI-1640, 25mM
HEPES, 5% heat inactivated-FBS, and 1x Antibiotic/Antimycotic. Mf that were released from
individual females after 18 hours were removed from the wells and counted. For the embryogram
analyses, individual adult female worms previously frozen in 0.5mL of 0.1% PBS-Triton X-100
(Sigma) were homogenized using a glass pestle to disrupt the cuticle and expose the reproductive
structures. Developing stages from the ovaries and uteri (oocyte, early morula, late morula, premf, pretzel mf and stretched mf, degenerated embryos) were assessed in a blinded fashion for
their developmental stages using an inverted microscope and hemocytometer. A minimum of 100
developmental stages were counted from each female and relative proportions were used to determine the means and standard deviations. n = 6–9 females per treatment group per timepoint [45].

Fluorescence imaging of female worm ovaries
Female B. pahangi worms removed from jirds from each group were frozen and shipped to
UC Santa Cruz for fluorescence analysis. Frozen worms were thawed at room temperature,
immediately fixed in 3.2% paraformaldehyde for 25 minutes and rinsed twice in PBST (PBS
plus 0.1% Triton-X100). Individual female uteri/ovaries were dissected from fixed tissue and
incubated overnight in RNAse A (10mg/mL) in PBST following similar protocols described by
Landmann et al., Serbus et al. and Foray et al. [45–49]. Tissues were then stained with propidium iodide (PI) (1mg/mL diluted 100X in PBST) for 30 seconds, rinsed twice in PBST and
then mounted in DAPI Vectashield mounting medium (Vector Labs). The distal tips of the
ovarian tissue were imaged on a Leica SP5 confocal microscope and single images were taken
at the mid-plane of the ovarian tissue for each distal tip. To measure the average Wolbachia
titer of each distal tip, Wolbachia puncta were counted by hand using the Cell Counter tool in
FIJI; the number of puncta was divided by the area of the tissue in each image (puncta/μm2).

Statistical analyses
Data were first tested for normality using the Shapiro-Wilk test of normality. When data did
not pass the normality test, a Mann-Whitney U test was conducted and when data did pass the
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normality test, a Student’s t-test was used. All significance levels were determined as compared
to the vehicle worms at the same timepoint. Individual percent reductions of Wolbachia were
calculated for each worm using the wsp copy number normalized to the Brugia gst copy number [28,29,38–40]. Wsp/gst ratios were calculated for each timepoint by subtracting the wsp/gst
ratios of treated worms from the mean wsp/gst ratio of vehicle worms and then dividing by the
mean wsp/gst ratio of vehicle worms for each respective timepoint. The means were then calculated to determine the average percent reduction. All statistical analyses were determined
using Prism 8 version 8.2.0 (272).

Supporting information
S1 Fig. Rifampicin treatment of Brugia pahangi-infected jirds does not reduce worm burden significantly at any timepoint. (A) Number of total worms recovered from the peritoneal
cavity of B. pahangi-infected jirds 1-week, 6-weeks, 17-weeks and 8-months post-first dose.
(B) Number of female worms recovered from the peritoneal cavity of B. pahangi-infected jirds
1-week, 6-weeks, 17-weeks and 8-months post-first dose. (C) Number of male worms recovered from the peritoneal cavity of B. pahangi-infected jirds 1-week, 6-weeks, 17-weeks and
8-months post-first dose. Data is presented as median ± 95% CI. n = 2–9 jirds per treatment
group per timepoint.
(PDF)
S2 Fig. Plasma concentrations peak 3 hours post-rifampicin treatment of Brugia pahangiinfected jirds. Plasma samples were collected at 0.5, 1, 3, 6 and 24 hours post-first dose from
B. pahangi infected jirds treated with oral doses of rifampicin 25 mg/kg twice a day for 7 days.
Analyses showed that plasma concentrations peaked at 3 hours post-first dose with a Cmax of
5.17x103 ng/mL. n = 3 jirds for all timepoints except n = 2 at 6 hours and n = 4 at 24 hours.
(PDF)
S1 Table. Results of Wolbachia titers from 3 experimental replicates after rifampicin treatment. qPCR analyses used worms from 3 separate cohorts of animals with data from two replicate experiments for each timepoint, except for the 17-week timepoint. Data are presented as
mean percent reductions based on control worms.
(PDF)
S2 Table. PacBio sequencing of Wolbachia using hybridization probe-capture.
(PDF)
S3 Table. Genetic variants identified in Wolbachia after rifampicin treatment.
(PDF)
S4 Table. Female worms recovered from jirds treated 6 weeks post-first dose had significantly higher numbers of degenerated embryos compared to those from the vehicle group.
The number in each cell is the mean of each embryonic stage ± the standard deviation.
(PDF)
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